Pfizer, Mylan Beat EpiPen Antitrust Suit, For Now

By Lauren Berg · July 26, 2021, 7:36 PM EDT

A Kansas federal judge on Monday tossed a lawsuit alleging Mylan Pharmaceuticals and Pfizer Inc. inflated the price of emergency allergy medication EpiPen, saying the pharmacy operator behind the suit doesn't...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

KPH Healthcare Services, Inc. v. Mylan N.V. et al

Case Number

Court

Kansas

Nature of Suit

Anti-Trust

Date Filed

February 14, 2020

Recent Articles By Lauren

May 21, 2024
Hawaii Wins $916M From Bristol-Myers, Sanofi Over Plavix
May 02, 2024
Walgreens Fights $1B Arb. Award Over COVID Test Contract
April 29, 2024
Pfizer Inks $25M Deal Ending Leftover Effexor Antitrust Claims
April 29, 2024
Boehringer Accused Of Monopolizing Inhaler Product Market
April 19, 2024
Judge Mulls Axing Biomedical Cos.' $25M Punitive Damages
April 09, 2024
Philips, Feds Enter Consent Decree Over Sleep Apnea Devices
April 05, 2024
'Take The Win,' Judge Tells Texas In HHS Abortion Pill Suit
March 21, 2024
5th Circ. Backs FDA's Vivid Warnings Of Cigarette Dangers
March 12, 2024
NYC Hospital Signs $17.3M 'Kickback' Deal With Feds, State
February 12, 2024
Meta Can't Trim Non-Facebook Users' Health Privacy Suit